Maze Therapeutics, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | -52.3% | +236.4% | +65.1% | |
| – | -67.9% | +491.2% | +73.4% | |
| – | -70.8% | +575.0% | -3.8% | |
| – | -70.8% | +575.0% | +73.7% | |
| – | – | – | – | |
| – | +26.7% | -29.0% | -3.4% | |
| – | -21.5% | +26.7% | +9.1% | |
| – | +3.8% | +3.2% | +3.5% | |
| – | +27.4% | -4.0% | -7.5% | |
| – | – | – | – | |
| – | -90.1% | +1,858.5% | +80.3% | |
| – | – | – | – | |
| – | +0.0% | +0.0% | -1.9% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.